A 26-week randomized, open-label, active-controlled, 2-treatment arm, parallel-group multi-center study, comparing the efficacy and safety of Soliqua™100/33 versus Lantus® in ethnically/racially diverse patients with type 2 diabetes mellitus inadequately controlled on basal insulin and oral antidiabetic agents with a 26-week extension period
Qualified Participants Must:T2DM diagnosed at least 1 year prior to the screening visit (signing of informed consent);
Uncontrolled diabetes as demonstrated by a screening centrally measured HbA1c between 7.5% and 10% (inclusive);
Patients who are Hispanics of any race, non-Hispanic black/African Americans or non-Hispanic Asians;
Age >=18 years of age at Visit 1;